InCarda at 2019 Stanford Biodesign New Arrhythmia Technologies Retreat

May 7, 2019 – Palo Alto, CA

At the 2019 Stanford Biodesign New Arrhythmia Technologies Retreat, InCarda’s Chief Medical Officer, Dr. Luiz Belardinelli, provided an overview of the pre-clinical and clinical development for InRhythm (flecainide for inhalation). Dr. Bellardinelli explained to the audience of cardiology experts how InRhythm’s target clinical profile is well suited to meeting the current need of acute pharmacological treatment that is rapid, effective at restoring normal sinus rhythm, and safe enough for patients to self-administer.

This Stanford Biodesign Retreat was designed as an expert forum of 60 key thought leaders and innovators to share their ideas about new and emerging technologies in arrhythmia management and diagnosis. For 2019, The Retreat was a Heart Rhythm Society (HRS) cosponsored program.

Conference website:



Back to News & Updates